EichorEICHOR
Condition: Previously Treated Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Previously Treated Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Erasca, Inc. · NCT06983743A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatmen
Phase 2 · 1 location(s) · Shanghai Cancer Hospital, China · NCT06901817Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agen
Phase 1/Phase 2 · 7 location(s) · Novartis Pharmaceuticals · NCT07468071A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · 402 location(s) · Pfizer · NCT07144280A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · 317 location(s) · AbbVie · NCT04928846Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously
Phase 3 · 32 location(s) · Fundación GECP · NCT06431633Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Im
Phase 1/Phase 2 · 117 location(s) · AbbVie · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · 152 location(s) · Revolution Medicines, Inc. · NCT06881784Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N
Phase 3 · 205 location(s) · AstraZeneca · NCT07291037Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · 386 location(s) · SWOG Cancer Research Network · NCT06616584A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/Phase 2 · 27 location(s) · Merck Sharp & Dohme LLC · NCT07286149A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 · 28 location(s) · Jazz Pharmaceuticals · NCT06695845Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Pat
Phase 2 · 1 location(s) · EuroCityClinic LLC · NCT07130032Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · 1229 location(s) · SWOG Cancer Research Network · NCT03851445A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · University of Chicago · NCT07603856Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell
Phase 2 · 44 location(s) · Merck Sharp & Dohme LLC · NCT06780098Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Phase 2 · 5 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT05631249A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Phase 3 · 2 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT06930794A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced No
Phase 3 · 274 location(s) · Bristol-Myers Squibb · NCT07361510EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
Phase N/A · 4 location(s) · Hedera Dx SA · NCT07096258A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the B
Phase 2 · 80 location(s) · AbbVie · NCT06568939A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cance
Phase 2 · 34 location(s) · Merck Sharp & Dohme LLC · NCT06780085The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06109558A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Phase 2 · 3 location(s) · Verastem, Inc. · NCT07659782A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea
Phase 3 · 29 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06908993
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.